TRI-FR at #ACC26: T-TEER in addition to standard-of-care medical therapy reduced the risk of death, #cvMI, stroke and hospitalization for #heartfailure compared with standard-of-care alone in patients with severe symptomatic #vhdTR.

Learn more: https://bit.ly/3PCWUVm #CardioSky

New multisociety consensus outlines operator & institutional requirements for tricuspid interventions & guidance for implementing & maintaining a transcatheter tricuspid valve intervention program in a rapidly evolving field.

Get the details in #JACC: https://bit.ly/4rUYP4T #vhdTR #TTVI #CardioSky

In the largest analysis of early T-TEER to date, the TRILUMINATE Pivotal trial found TriClip is both safe and effective for treating symptomatic patients w/ severe #vhdTR. At just 30 days, patients saw ⬆️ improvements in QoL.

Watch more from #TCT2025: https://bit.ly/49ewkt9 #CardioSky #MedSky

🎥 Dr. Fred Kusumoto shares the importance of clinical guidance beyond traditional #ClinicalGuidelines, & shares takeaways from 🆕 expert consensus decision pathway on tricuspid regurgitation (TR).

📖 Read: https://bit.ly/4ncVbSp

#JACC #ACCClinicalDoc #CardioSky #vhdTR @jaccjournals.bsky.social

A 🆕 ECDP addressing "10 issues for the clinician in TR evaluation & management" focuses specifically on patients w/ secondary #vhdTR in the chronic setting & is intended to serve as a bridge to a future update of ACC/AHA #cvVHD guideline.

Read more: https://bit.ly/4ncVbSp

#JACC #CardioSky #MedSky

A new ECDP addressing "10 issues for the clinician in TR evaluation & management" focuses specifically on patients with secondary TR in the chronic setting & intended to serve as a bridge to a future update of ACC/AHA #VHD guideline. Get the details: https://bit.ly/4ngIbvd

#JACC #vhdTR #CardioSky

🆕 From #CardioSmart: Tricuspid Regurgitation Hub: bit.ly/41wWEuC

Includes:
✅ infographic explaining the tricuspid valve, signs, symptoms, treatments & other considerations
✅ decision aid to guide patient-clinician discussions

#vhdTR #CardioSky #MedSky